Form 4: Exelixis EVP & General Counsel, Jeffrey Hessekiel, Reports Acquisition of Performance-Based Restricted Stock Units

Jeffrey Hessekiel, EVP & General Counsel of Exelixis, reports the acquisition of performance-based restricted stock units and adjustments to holdings in common stock and 401(k).

Summary

• On March 31, 2025, Jeffrey Hessekiel, EVP & General Counsel of Exelixis, reported changes in beneficial ownership to the SEC.
• Hessekiel acquired 154,070 performance-based restricted stock units (PSUs) under the 2017 Equity Incentive Plan.
• These PSUs vest if the volume-weighted average closing price of Exelixis' common stock equals or exceeds $60 per share for 90 consecutive calendar days within a five-year period, and if Hessekiel remains employed through the fifth anniversary of the grant date.
• Hessekiel directly owns 751,678 shares of Exelixis common stock, including shares issuable upon vesting of restricted stock units (RSUs) and PSUs.
• Hessekiel also indirectly owns 999 shares of common stock through the Exelixis, Inc. 401(k) Plan.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of executive compensation and stock ownership, which is generally neutral. The positive aspect is the alignment of executive incentives with company performance.

Positives

• The acquisition of performance-based restricted stock units aligns Hessekiel's interests with the company's performance goals.
• The vesting conditions of the PSUs incentivize long-term value creation and continued employment.

Risks

• The vesting of the PSUs is contingent on the company's stock price reaching $60, which may not occur.
• Hessekiel's employment must continue for five years for the PSUs to fully vest, creating a potential risk if employment is terminated.

Future Outlook

The vesting of the PSUs is dependent on the future performance of Exelixis' common stock and Hessekiel's continued employment.

Industry Context

This filing is a routine disclosure of changes in beneficial ownership by a company executive, which is common in publicly traded companies. It reflects the executive's compensation structure and alignment with shareholder interests.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded biotechnology companies to incentivize executives to achieve specific performance targets.
• The vesting conditions, such as stock price targets and continued employment, are typical in executive compensation packages.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the acquisition of PSUs as a positive sign, aligning executive interests with company performance.
• Employees may see this as a standard part of executive compensation.

Key Dates

Keywords

Exelixis, Hessekiel, Performance-Based Restricted Stock Units, PSU, RSU, Beneficial Ownership, SEC Form 4, Equity Incentive Plan, Common Stock, 401(k)